Rebecca Previs: HRD Testing Is Now Available Through OmniSeq INSIGHT
Rebecca Previs, Director of Medical Affairs – Oncology at Labcorp, shared a post on LinkedIn:
“As a gynecologic oncologist, we know how critical it is to identify patients who may benefit from PARP inhibitors early in their treatment journey. That’s why I’m excited that HRD testing is now available through OmniSeq INSIGHT for patients with ovarian, fallopian tube, and primary peritoneal cancers.
Homologous recombination deficiency (HRD) is a clinically relevant biomarker – it helps us personalize care by identifying patients most likely to benefit from maintenance therapy with PARP inhibitors.
All women with these cancers should be tested for germline and somatic BRCA mutations and HRD status—ideally during initial therapy. These results directly guide treatment decisions and can improve outcomes for patients facing a high risk of recurrence.
Results are delivered in just 7–10 days, with quantitative genomic instability scoring (GIS) that brings clarity to complex cases.
Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared this post, adding:
“Big news. I’m so excited and thrilled for our patients!
Huge congratulations to our whole team at Labcorp and OmniSeq!”
More posts featuring Rebecca Previs and Heidi Ko.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023